View Older Stories View More Recent Stories
-
Stifel Downgrades BioMarin Pharmaceutical Inc. (BMRN) to Hold, 'Stock Might Even Be Too Cheap, But It's Getting Harder to See the Path'
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered at Bernstein Amid 'Tough NT Setup'
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered at Truist; 'Competitive Pressures Mounting'
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $66 at RBC Capital
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $55 at H.C. Wainwright
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $73 at Stifel
-
Wolfe on BioMarin Pharmaceutical Inc. (BMRN): 'Divesting Roctavian Is A Rock Solid Move'
-
BioMarin Pharma (BMRN) Tops Q3 EPS by 20c
-
Bernstein's US Biotech 3Q25 Preview: 'Expect Beats from ALNY and REGN'
-
Cantor Fitzgerald Cuts BioMarin (BMRN) PT to $80 Ahead of 3Q Earnings
-
H.C. Wainwright Starts BioMarin Pharmaceutical Inc. (BMRN) at Neutral
-
Why public perception matters so much for biotech valuations
-
Oppenheimer Reiterates Outperform Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $95 at Bernstein SocGen Group
-
Stifel Reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
Cantor Fitzgerald Reiterates Overweight Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
Bernstein Reiterates Outperform Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
TD Cowen Reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $114 at UBS
-
After-hours movers: Palantir, Hims & Hers, Vertex Pharma and more
-
BioMarin Pharma (BMRN) Tops Q2 EPS by 61c ; Offers Guidance
-
Wolfe Research Reiterates Outperform Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
Morgan Stanley Assumes BioMarin Pharmaceutical Inc. (BMRN) at Overweight
-
BioMarin Pharma (BMRN) Announces Completion of Acquisition of Inozyme (INZY)
-
Jefferies Reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
BioMarin Pharma (BMRN) Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN at International Society on Thrombosis and Haemostasis 2025 Congress
-
FDA Cell and Gene Therapy Roundtable 'bullish for the space' - Stifel
-
Stifel Reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
BioMarin Pharmaceutical Inc. (BMRN) PT Raised at Bernstein Following Inozyme Deal
-
TD Cowen Reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN) Following Inozyme Deal
-
Evercore ISI on BioMarin (BMRN): 'INZY Acquisition Looks Like a Solid Addition to the Growing and Often Overlooked Enzyme Therapy Biz'
-
Stifel Comments on BioMarin Pharma (BMRN): 'Acquisition of INZY A Strong Strategic Fit for BMRN; The Type of Asset That Offers Value Arbitrage'
-
BioMarin Pharma (BMRN) Announces Acquisition of Inozyme Pharma (INZY) for $4 Per Share
-
BioMarin Pharma (BMRN) Presents New Data for VOXZOGO in Children with Achondroplasia
-
Cantor Fitzgerald Reiterates Overweight Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
BioMarin Pharma (BMRN) Tops Q1 EPS by 43c
-
Oppenheimer Reiterates Outperform Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
Bernstein Recommends Three US Biotech Stocks Amid 'Heightened Regulatory Uncertainty'
-
BioMarin Pharma (BMRN) Announces Positive Pivotal Data for PALYNZIQ in Adolescents with Phenylketonuria
-
Citi Reiterates Neutral Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
Bernstein provides 2025 M&A outlook for U.S. Biotech and Pharma
-
How could tariffs shake up the pharma sector?
-
BioMarin Pharma (BMRN) Appoints Timothy P. Walbert to its Board
-
Oppenheimer Upgrades BioMarin Pharmaceutical Inc. (BMRN) to Outperform
-
Cantor Fitzgerald Reiterates Overweight Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
BMO Reiterates Outperform on BioMarin Pharmaceutical Inc. (BMRN) as 'Voxzogo Growth Continues'
-
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $126 at Piper Sandler; 'Strong Execution All Around'
-
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $80 at Scotiabank
-
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $91 at Stifel
-
After-hours movers: Carvana, Klaviyo, NerdWallet, BioMarin Pharma, and more

